{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:40:47Z","timestamp":1761093647426,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["5T32HD069054"],"award-info":[{"award-number":["5T32HD069054"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R01-HL090941"],"award-info":[{"award-number":["R01-HL090941"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.bcmd.2017.08.007","type":"journal-article","created":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T00:17:48Z","timestamp":1502237868000},"page":"143-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Opportunities for model-based precision dosing in the treatment of sickle cell anemia"],"prefix":"10.1016","volume":"67","author":[{"given":"Min","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander A.","family":"Vinks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2017.08.007_bb0005","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/cpt1979263294","article-title":"Forecasting individual pharmacokinetics","volume":"26","author":"Sheiner","year":"1979","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00003088-199834010-00003","article-title":"Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new \u2018multiple model\u2019 dosage design, Bayesian feedback and individualised target goals","volume":"34","author":"Jelliffe","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/asheducation.V2015.1.436.3917688","article-title":"Optimizing hydroxyurea therapy for sickle cell anemia","volume":"2015","author":"Ware","year":"2015","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.bcmd.2017.08.007_bb0020","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bcp.12851","article-title":"Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia","volume":"81","author":"Dong","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.24255","article-title":"Effects of hydroxyurea treatment for patients with hemoglobin SC disease","volume":"91","author":"Luchtman-Jones","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0030","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2017.08.007_bb0035","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.bcmd.2017.08.007_bb0040","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM198404053101401","article-title":"Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea","volume":"310","author":"Letvin","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0045","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2010.023325","article-title":"Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model","volume":"95","author":"Lebensburger","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2017.08.007_bb0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/asheducation-2009.1.62","article-title":"Advances in the use of hydroxyurea","author":"Ware","year":"2009","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.bcmd.2017.08.007_bb0055","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2011-07-364190","article-title":"Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia","volume":"118","author":"Ware","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.08.007_bb0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-6-30","article-title":"Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen","volume":"6","author":"Paule","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0065","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF01060053","article-title":"Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data","volume":"8","author":"Sheiner","year":"1980","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0070","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.aap.2005.03.012","article-title":"Bayesian ranking of sites for engineering safety improvements: decision parameter, treatability concept, statistical criterion, and spatial dependence","volume":"37","author":"Miaou","year":"2005","journal-title":"Accid. Anal. Prev."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fncom.2016.00110","article-title":"Simultaneous Bayesian estimation of excitatory and inhibitory synaptic conductances by exploiting multiple recorded trials","volume":"10","author":"Lankarany","year":"2016","journal-title":"Front. Comput. Neurosci."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147311","article-title":"Bayesian estimation of small effects in exercise and sports science","volume":"11","author":"Mengersen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2017.08.007_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144435","article-title":"Modeling the offensive-defensive interaction and resulting outcomes in basketball","volume":"10","author":"Lamas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2017.08.007_bb0090","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/jps.2600711209","article-title":"Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods","volume":"71","author":"Sheiner","year":"1982","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0095","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199310000-00005","article-title":"Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control","volume":"15","author":"Jelliffe","year":"1993","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","article-title":"Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis","volume":"21","author":"van Lent-Evers","year":"1999","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0105","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0110","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cpt.339","article-title":"Therapeutic optimization as part of the precision medicine paradigm","volume":"99","author":"Vinks","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0115","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cmpb.2012.05.005","article-title":"PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool","volume":"108","author":"Nyberg","year":"2012","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0120","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40262-012-0020-y","article-title":"Benchmarking therapeutic drug monitoring software: a review of available computer tools","volume":"52","author":"Fuchs","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0010-4825(92)90011-B","article-title":"MW\/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring","volume":"22","author":"Proost","year":"1992","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0135","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FTD.0000000000000276","article-title":"Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software","volume":"38","author":"Neely","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0140","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1128\/AAC.02664-14","article-title":"Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy","volume":"58","author":"Felton","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0145","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.phrs.2011.04.008","article-title":"Nonparametric population modeling and Bayesian analysis","volume":"64","author":"Jelliffe","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0150","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0091270009356572","article-title":"Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician","volume":"50","author":"Neely","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0155","doi-asserted-by":"crossref","DOI":"10.1373\/clinchem.2016.263715","article-title":"Stable-isotope dilution HPLC-electrospray ionization tandem mass spectrometry method for quantifying hydroxyurea in dried blood samples","author":"Marahatta","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0160","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s40262-014-0151-4","article-title":"Clinical pharmacology of deferasirox","volume":"53","author":"Tanaka","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0165","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2010-01-265405","article-title":"Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring","volume":"115","author":"Gaziev","year":"2010","journal-title":"Blood"},{"issue":"Suppl. 3","key":"10.1016\/j.bcmd.2017.08.007_bb0170","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1399-3046.7.s3.2.x","article-title":"Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation","volume":"7","author":"Bostrom","year":"2003","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0175","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.bbmt.2015.01.015","article-title":"Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial","volume":"21","author":"Horan","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0180","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/pbc.25376","article-title":"New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation","volume":"62","author":"Gaziev","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcmd.2017.08.007_bb0185","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing busulfan-based conditioning: considerations from the American society for blood and marrow transplantation practice guidelines committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0190","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1177\/0091270009357430","article-title":"Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration","volume":"50","author":"Salinger","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0195","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-13-1960","article-title":"Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization","volume":"20","author":"McCune","year":"2014","journal-title":"Clin. Cancer Res."},{"year":"2016","series-title":"US Prescribing Information","author":"N. EXJADE\u00ae (deferasirox)","key":"10.1016\/j.bcmd.2017.08.007_bb0200"},{"key":"10.1016\/j.bcmd.2017.08.007_bb0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/17425255.2012.640674","article-title":"Deferasirox: pharmacokinetics and clinical experience","volume":"8","author":"Galanello","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0210","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/17512433.1.2.231","article-title":"Once-daily oral deferasirox for the treatment of transfusional iron overload","volume":"1","author":"Galanello","year":"2008","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPH.0000000000000291","article-title":"Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study","volume":"37","author":"Styles","year":"2015","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.bcmd.2017.08.007_bb0220","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2014-06-583351","article-title":"Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use","volume":"125","author":"Telen","year":"2015","journal-title":"Blood"},{"journal-title":"The Food and Drug Administration","year":"2016","key":"10.1016\/j.bcmd.2017.08.007_bb0225"},{"key":"10.1016\/j.bcmd.2017.08.007_bb0230","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0022-3565(24)38962-1","article-title":"Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats","volume":"295","author":"Friberg","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979617300281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979617300281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:33:07Z","timestamp":1761049987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979617300281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":46,"alternative-id":["S1079979617300281"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2017.08.007","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities for model-based precision dosing in the treatment of sickle cell anemia","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2017.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}